MoonLake Immunotherapeutics (MLTX) Enterprise Value (2020 - 2026)
MoonLake Immunotherapeutics (MLTX) posted quarterly Enterprise Value of -$357.9 million for Q1 2026, up 24.66% year-over-year from -$287.1 million in Q1 2025, and up 9.15% quarter-over-quarter from -$394.0 million in Q4 2025.
MoonLake Immunotherapeutics (MLTX) Enterprise Value (2020 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' Enterprise Value history runs 7 years deep, the most recent figure standing at -$357.9 million for Q1 2026.
- In Q1 2026, Enterprise Value rose 24.66% year-over-year to -$357.9 million; the TTM figure through Mar 2026 stood at -$357.9 million (up 24.66% YoY), while the FY2025 annual figure was -$394.0 million, up 10.76% from the prior year.
- Enterprise Value for Q1 2026 stood at -$357.9 million, up from -$394.0 million in the prior quarter.
- The five-year high for Enterprise Value was $31.0 million in Q2 2022, with the low at -$537.2 million in Q1 2024.
- The 5-year median for Enterprise Value is -$420.9 million (2025), against an average of -$331.9 million.
- Peak annual rise in Enterprise Value reached 2928.04% in 2022, while the deepest fall reached 8533.99% in 2022.
- MoonLake Immunotherapeutics' Enterprise Value stood at -$52.2 million in 2022, then tumbled by 843.98% to -$493.2 million in 2023, then rose by 10.49% to -$441.5 million in 2024, then gained by 10.76% to -$394.0 million in 2025, then rose by 9.15% to -$357.9 million in 2026.
- Business Quant data shows MLTX's Enterprise Value at -$357.9 million in Q1 2026, -$394.0 million in Q4 2025, and -$378.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | MoonLake Immunotherapeutics | 1.40 Bn | 864.68 Mn | - | -537.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -537.03 Mn |
| Mar 31, 2026 | -357.92 Mn |
| Dec 31, 2025 | -393.97 Mn |
| Sep 30, 2025 | -378.19 Mn |
| Jun 30, 2025 | -420.87 Mn |
| Mar 31, 2025 | -475.07 Mn |
| Dec 31, 2024 | -441.46 Mn |
| Sep 30, 2024 | -486.62 Mn |
| Jun 30, 2024 | -510.43 Mn |
| Mar 31, 2024 | -537.22 Mn |
| Dec 31, 2023 | -493.19 Mn |
| Sep 30, 2023 | -431.27 Mn |
| Jun 30, 2023 | -492.47 Mn |
| Mar 31, 2023 | -45.92 Mn |
| Dec 31, 2022 | -52.25 Mn |
| Sep 30, 2022 | -56.18 Mn |
| Jun 30, 2022 | 31.04 Mn |
| Mar 31, 2022 | -101.02 Mn |
| Dec 31, 2021 | -8.04 Mn |
| Sep 30, 2021 | -1.03 Mn |